Skip to main content
NCBI home page
Biochemical Journal logoLink to Biochemical Journal
. 1995 Apr 1;307(Pt 1):17–22. doi: 10.1042/bj3070017

The apolipoprotein B3304-3317 peptide as an inhibitor of the lipoprotein (a):apolipoprotein B-containing lipoprotein interaction.

V N Trieu 1, U Olsson 1, W J McConathy 1
PMCID: PMC1136739  PMID: 7717972

Abstract

Lipoprotein (a) [Lp(a)] is a risk factor for coronary artery disease. It is characterized by apolipoprotein (a) [apo(a)] disulphide linked to apolipoprotein B (apoB), by Cys4057 of apo(a) and possibly Cys3734 of apoB. We call this the covalent apo(a):apoB-Lp interaction, to distinguish it from the non-covalent Lp(a):apoB-Lp interaction, mediated by the proline-binding kringle-4-like domain(s) of Lp(a). The Lp(a):apoB-Lp interaction was inhibited by an apoB peptide spanning residues 3304-3317. This peptide was found by a computerized search for sites on apoB similar to the plasminogen's kringle-4-binding site of alpha 2-antiplasmin. It probably constitutes part of the Lp(a)-binding site on apoB because: (1) it corresponds to the alpha 2-antiplasmin minimum binding domain for plasminogen's kringle-4; (2) the competitive nature of inhibition [KI = (1.5 +/- 0.7) x 10(-4) M, n = 5] suggested that it and apoB-Lp bound to Lp(a) by the same mechanism at the same site; and (3) it specifically bound Lp(a) and not apoB-Lp, and the bound Lp(a) was dissociated by inhibitors of the Lp(a):apoB-Lp interaction, 6-aminohexanoic acid and L-proline. Inhibition was independent of its proline residue, suggesting that proline in the context of a peptide is not a ligand for the kringle(s) which mediated the binding of Lp(a) to apoB-Lp.

Full text

PDF
17

Images in this article

19Figure 2
on p.19
20Figure 4
on p.20
20Figure 5
on p.20

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Armstrong V. W., Cremer P., Eberle E., Manke A., Schulze F., Wieland H., Kreuzer H., Seidel D. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. Atherosclerosis. 1986 Dec;62(3):249–257. doi: 10.1016/0021-9150(86)90099-7. [DOI] [PubMed] [Google Scholar]
  2. Bottalico L. A., Keesler G. A., Fless G. M., Tabas I. Cholesterol loading of macrophages leads to marked enhancement of native lipoprotein(a) and apoprotein(a) internalization and degradation. J Biol Chem. 1993 Apr 25;268(12):8569–8573. [PubMed] [Google Scholar]
  3. Brunner C., Kraft H. G., Utermann G., Müller H. J. Cys4057 of apolipoprotein(a) is essential for lipoprotein(a) assembly. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11643–11647. doi: 10.1073/pnas.90.24.11643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chen G. C., Zhu S., Hardman D. A., Schilling J. W., Lau K., Kane J. P. Structural domains of human apolipoprotein B-100. Differential accessibility to limited proteolysis of B-100 in low density and very low density lipoproteins. J Biol Chem. 1989 Aug 25;264(24):14369–14375. [PubMed] [Google Scholar]
  5. Dahlen G. H., Guyton J. R., Attar M., Farmer J. A., Kautz J. A., Gotto A. M., Jr Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 1986 Oct;74(4):758–765. doi: 10.1161/01.cir.74.4.758. [DOI] [PubMed] [Google Scholar]
  6. Durrington P. N., Ishola M., Hunt L., Arrol S., Bhatnagar D. Apolipoproteins (a), AI, and B and parental history in men with early onset ischaemic heart disease. Lancet. 1988 May 14;1(8594):1070–1073. doi: 10.1016/s0140-6736(88)91895-8. [DOI] [PubMed] [Google Scholar]
  7. Fless G. M., ZumMallen M. E., Scanu A. M. Physicochemical properties of apolipoprotein(a) and lipoprotein(a-) derived from the dissociation of human plasma lipoprotein (a). J Biol Chem. 1986 Jul 5;261(19):8712–8718. [PubMed] [Google Scholar]
  8. Guevara J., Jr, Spurlino J., Jan A. Y., Yang C. Y., Tulinsky A., Prasad B. V., Gaubatz J. W., Morrisett J. D. Proposed mechanisms for binding of apo[a] kringle type 9 to apo B-100 in human lipoprotein[a]. Biophys J. 1993 Mar;64(3):686–700. doi: 10.1016/S0006-3495(93)81428-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hofmann S. L., Eaton D. L., Brown M. S., McConathy W. J., Goldstein J. L., Hammer R. E. Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice. J Clin Invest. 1990 May;85(5):1542–1547. doi: 10.1172/JCI114602. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kamanna V. S., Stiers D. L., Lee D. M. Rat apolipoprotein B differs in solubility properties from human apolipoprotein B. Biochim Biophys Acta. 1990 Mar 12;1043(1):119–121. doi: 10.1016/0005-2760(90)90119-i. [DOI] [PubMed] [Google Scholar]
  11. Koschinsky M. L., Côté G. P., Gabel B., van der Hoek Y. Y. Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100. J Biol Chem. 1993 Sep 15;268(26):19819–19825. [PubMed] [Google Scholar]
  12. Koschinsky M. L., Tomlinson J. E., Zioncheck T. F., Schwartz K., Eaton D. L., Lawn R. M. Apolipoprotein(a): expression and characterization of a recombinant form of the protein in mammalian cells. Biochemistry. 1991 May 21;30(20):5044–5051. doi: 10.1021/bi00234a029. [DOI] [PubMed] [Google Scholar]
  13. Kostner G. M., Grillhofer H. K. Lipoprotein(a) mediates high affinity low density lipoprotein association to receptor negative fibroblasts. J Biol Chem. 1991 Nov 5;266(31):21287–21292. [PubMed] [Google Scholar]
  14. Kostner G. M. Interaction of Lp(a) and of apo(a) with liver cells. Arterioscler Thromb. 1993 Jul;13(7):1101–1109. doi: 10.1161/01.atv.13.7.1101. [DOI] [PubMed] [Google Scholar]
  15. McConathy W. J., Koren E., Wieland H., Campos E. M., Lee D. M., Kloer H. U., Alaupovic P. Evaluation of immunoaffinity chromatography for isolating human lipoproteins containing apolipoprotein B. J Chromatogr. 1985 Jul 12;342(1):46–66. [PubMed] [Google Scholar]
  16. McConathy W. J., Trieu V. N., Klör H. U., Corder C. N. Lp(a) and plasma triglyceride-rich lipoproteins. Klin Wochenschr. 1990;68 (Suppl 22):117–119. [PubMed] [Google Scholar]
  17. McConathy W. J., Trieu V. N., Koren E., Wang C. S., Corder C. C. Triglyceride-rich lipoprotein interactions with Lp(a). Chem Phys Lipids. 1994 Jan;67-68:105–113. doi: 10.1016/0009-3084(94)90129-5. [DOI] [PubMed] [Google Scholar]
  18. McConathy W. J., Trieu V. N. Lp(a) interactions. Prog Lipid Res. 1991;30(2-3):195–203. doi: 10.1016/0163-7827(91)90016-x. [DOI] [PubMed] [Google Scholar]
  19. McConathy W. J., Wang C. S. Inhibition of lipoprotein lipase by the receptor-binding domain of apolipoprotein E. FEBS Lett. 1989 Jul 17;251(1-2):250–252. doi: 10.1016/0014-5793(89)81464-4. [DOI] [PubMed] [Google Scholar]
  20. McLean J. W., Tomlinson J. E., Kuang W. J., Eaton D. L., Chen E. Y., Fless G. M., Scanu A. M., Lawn R. M. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987 Nov 12;330(6144):132–137. doi: 10.1038/330132a0. [DOI] [PubMed] [Google Scholar]
  21. Sandholzer C., Feussner G., Brunzell J., Utermann G. Distribution of apolipoprotein(a) in the plasma from patients with lipoprotein lipase deficiency and with type III hyperlipoproteinemia. No evidence for a triglyceride-rich precursor of lipoprotein(a). J Clin Invest. 1992 Nov;90(5):1958–1965. doi: 10.1172/JCI116074. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Smith T. F., Waterman M. S. Identification of common molecular subsequences. J Mol Biol. 1981 Mar 25;147(1):195–197. doi: 10.1016/0022-2836(81)90087-5. [DOI] [PubMed] [Google Scholar]
  23. Sugiyama N., Sasaki T., Iwamoto M., Abiko Y. Binding site of alpha 2-plasmin inhibitor to plasminogen. Biochim Biophys Acta. 1988 Jan 4;952(1):1–7. doi: 10.1016/0167-4838(88)90094-5. [DOI] [PubMed] [Google Scholar]
  24. Sullivan D. R., Lam C. W., Jessup W., Dean R. T., Hensley W. J. Postprandial changes in apolipoprotein(a) concentration of triglyceride-rich lipoproteins can be reproduced by in vitro incubation: implications for underlying mechanism. Atherosclerosis. 1993 Nov;103(2):139–147. doi: 10.1016/0021-9150(93)90257-u. [DOI] [PubMed] [Google Scholar]
  25. Trieu V. N., McConathy W. J. Lipoprotein(a) binding to other apolipoprotein B containing lipoproteins. Biochemistry. 1990 Jun 26;29(25):5919–5924. doi: 10.1021/bi00477a006. [DOI] [PubMed] [Google Scholar]
  26. Trieu V. N., Zioncheck T. F., Lawn R. M., McConathy W. J. Interaction of apolipoprotein(a) with apolipoprotein B-containing lipoproteins. J Biol Chem. 1991 Mar 25;266(9):5480–5485. [PubMed] [Google Scholar]
  27. Yang C. Y., Chen S. H., Gianturco S. H., Bradley W. A., Sparrow J. T., Tanimura M., Li W. H., Sparrow D. A., DeLoof H., Rosseneu M. Sequence, structure, receptor-binding domains and internal repeats of human apolipoprotein B-100. Nature. 1986 Oct 23;323(6090):738–742. doi: 10.1038/323738a0. [DOI] [PubMed] [Google Scholar]
  28. Ye S. Q., Trieu V. N., Stiers D. L., McConathy W. J. Interactions of low density lipoprotein2 and other apolipoprotein B-containing lipoproteins with lipoprotein(a). J Biol Chem. 1988 May 5;263(13):6337–6343. [PubMed] [Google Scholar]
  29. Zioncheck T. F., Powell L. M., Rice G. C., Eaton D. L., Lawn R. M. Interaction of recombinant apolipoprotein(a) and lipoprotein(a) with macrophages. J Clin Invest. 1991 Mar;87(3):767–771. doi: 10.1172/JCI115079. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES